News
Successful IGJ inspection completed
We are proud to share that last week BioConnection successfully completed a three-day inspection by the Healthcare and Youth Inspectorate (IGJ), conducted on behalf of the European Medicines Agency (EMA). This result confirms our commitment to quality and reliability...
Successful IGJ inspection completed
We are proud to share that last week BioConnection successfully completed a three-day inspection by the Healthcare and Youth Inspectorate (IGJ), conducted on behalf of the European Medicines Agency (EMA). This result confirms our commitment to quality and reliability...
BioConnection is honoured that AIMM Therapeutics has become our customer.
With our capabilities from our facility in Oss, the Netherlands, we are able to assist AIMM Therapeutics in the development of their groundbreaking...
Announcement: Large scale sterile GMP production capacity available for COVID-19 programs in our EMA and US-FDA certified facility
BioConnection B.V. / Oss, The Netherlands BioConnection has sterile drug product production capacity available for COVID-19 programs BioConnection...
Announcement: Sterile GMP production capacity available to overcome Covid-19 pandemic
BioConnection B.V. / Oss, The Netherlands / April 9, 2020 BioConnection has sterile production capacity available for the battle against the...
Lava Therapeutics and BioConnection cooperate to improve cancer treatment
BioConnection announces that Lava Therapeutics (LAVA), a biotechnology company creating and developing next-generation γδ T cell engaging bispecific...
Covid-19 update
Oss, The Netherlands, March 18, 2020. BioConnection has taken precautions related to the global outbreak of the Covid-19 virus. To start with; we...
BioConnection invests in expansion of its current production capacity with a second production line
Oss, The Netherlands, April 8, 2019. BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the...